TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06663319: A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies

Sponsor: Janssen Research & Development, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06663319 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06663319 Rescue Dossier →